SNGX
Soligenix, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Soligenix has 7 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceWe also initiated a development agreement with Emergent BioSolutions, Inc. ("EBS") to implement a commercially viable, scalable production technology for the RiVax ® drug substance protein antigen.
SNGX 10-Kaccession 0001104659-26-037701
SentenceWe currently rely on license agreements from New York University, Yeda Research and Development Company Ltd., the University of Texas Southwestern Medical Center, the University of British Columbia, and George B. McDonald, MD as well as sublicense agreement from VitriVax for the rights to commercialize key product candidates.
SNGX 10-Kaccession 0001104659-26-037701
SentenceDuring April 2020, we obtained an exclusive worldwide license for CoVaccine HT™, a novel vaccine adjuvant, from SERB Pharmaceuticals (formerly BTG Specialty Pharmaceuticals, a division of Boston Scientific Corporation) ("SERB"), for the fields of coronavirus infection (including SARS-CoV-2, the cause of COVID-19), and pandemic flu.
SNGX 10-Kaccession 0001104659-26-037701
SentenceWe currently rely on license agreements from New York University, Yeda Research and Development Company Ltd., the University of Texas Southwestern Medical Center, the University of British Columbia, and George B. McDonald, MD as well as sublicense agreement from VitriVax for the rights to commercialize key product candidates.
SNGX 10-Kaccession 0001104659-26-037701
SentenceWe currently rely on license agreements from New York University, Yeda Research and Development Company Ltd., the University of Texas Southwestern Medical Center, the University of British Columbia, and George B. McDonald, MD as well as sublicense agreement from VitriVax for the rights to commercialize key product candidates.
SNGX 10-Kaccession 0001104659-26-037701
SentenceWe currently rely on license agreements from New York University, Yeda Research and Development Company Ltd., the University of Texas Southwestern Medical Center, the University of British Columbia, and George B. McDonald, MD as well as sublicense agreement from VitriVax for the rights to commercialize key product candidates.
SNGX 10-Kaccession 0001104659-26-037701
SentenceWe currently rely on license agreements from New York University, Yeda Research and Development Company Ltd., the University of Texas Southwestern Medical Center, the University of British Columbia, and George B. McDonald, MD as well as sublicense agreement from VitriVax for the rights to commercialize key product candidates.
SNGX 10-Kaccession 0001104659-26-037701
SentenceIn September 2016, we and SciClone Pharmaceuticals, Inc. ("SciClone") entered into an exclusive license agreement, pursuant to which we granted rights to SciClone to develop, promote, market, distribute and sell SGX942 in defined territories.
SNGX 10-Kaccession 0001104659-26-037701
Soligenix, Inc.
0.35
Largest filed tie
—
+62.12%
shares held · 8 largest managers
Expected move
No implied move.